Skip to main content
    N

    Nurix Therapeutics Inc (NRIX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $14.24
    -0.49 (-3.33%)

    Market Cap: $1.61B

    Last updated: Nov 17, 2026 at 4:25 PM ET

    Nurix Therapeutics Inc (NRIX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Nurix Therapeutics (NRIX) has a market cap of $1.61B and an enterprise value of $889.01M. Revenue grew 738.76% over the last 12 months from the 12 months before. Its share count is up 32.56% from a year earlier.

    Total Valuation

    Enterprise value is 44.76% below the market cap, as cash exceeds debt.

    Market Cap$1.61B
    Enterprise Value$889.01M
    Latest price (Nov 17, 2026)$14.24

    Key Dates

    The next earnings report is expected on Jan 26, 2027, covering the quarter ending Nov 30, 2026.

    Next Earnings DateJan 26, 2027 (expected)
    Last Earnings DateOct 12, 2026
    Fiscal Year EndNovember

    Share Statistics

    The share count rose 0.43% in the quarter ended Aug 31, 2026 and grew 23.81% a year over 2 years.

    Shares Outstanding111.56M
    Shares Change (YoY)+32.56%
    Shares Change (QoQ)+0.43%
    Share Count Growth (2Y CAGR)+23.81%

    Valuation Ratios

    Sales and book value multiples are 2.3x and 1.6x.

    P/E Ratio6.2x
    Forward P/E5.3x
    P/S Ratio2.3x
    Forward P/S2.2x
    P/B Ratio1.6x
    P/FCF Ratio4.3x
    P/OCF Ratio4.2x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 2.9x EBITDA and 2.3x free cash flow.

    EV / Earnings3.0x
    EV / Sales1.3x
    EV / EBITDA2.9x
    EV / FCF2.3x

    Price Statistics

    The stock is up 11.25% over 52 weeks and trades 37.54% below its 50-day average.

    Beta (1Y)1.02
    52-Week Change+11.25%
    1-Month Change-42.88%
    3-Month Change-48.76%
    6-Month Change-6.56%
    5-Year Change-19.88%
    Total Return (1Y)+11.25%
    Total Return (3Y CAGR)+31.23%
    Total Return (5Y CAGR)-15.45%
    Return vs SPY (1Y)+0.74%
    Max Drawdown (1Y)-48.76%
    Max Drawdown (3Y)-70.72%
    Sharpe Ratio (1Y)0.16
    Correlation with SPY (1Y)0.19
    50-Day Average$22.80
    200-Day Average$20.10
    52-Week Range$12.61 to $28.23
    RSI (14 Days)24.1
    Average Volume (20 Days)3.77M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 8.44x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio8.44x
    Quick Ratio8.44x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is 30.45% over the last 12 months, against a 5-year average of -50.25%.

    Return on Equity (ROE)30.45%
    Return on Assets (ROA)24.67%
    ROE (5Y Average)-50.25%
    ROA (5Y Average)-35.14%
    ROIC (5Y Average)-53.02%
    Asset Turnover0.82x
    Receivables Turnover70.19x

    Taxes

    Income tax took 4.33% of pretax income over the last 12 months.

    Income Tax (TTM)$13.34M
    Effective Tax Rate4.33%

    Scores

    NRIX has an Altman Z-Score of 5.83, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score5.83
    Altman Z ZoneSafe
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $701.94M over the last 12 months.

    Revenue$701.94M
    Revenue Growth (YoY)+738.76%
    Gross Profit$701.94M
    Operating Income$289.66M
    Pretax Income$308.21M
    Net Income$294.88M
    Reported EPS (TTM)$2.31

    Trailing 12 months through Aug 31, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 80.69% of the $1.20B in total assets.

    Cash and Equivalents$720.24M
    Total Debt$0
    Net Cash$720.24M
    Net Cash Per Share$6.46
    Working Capital$972.95M
    Shareholder Equity$968.31M
    Book Value Per Share$8.68
    Total Assets$1.20B
    Total Liabilities$226.99M

    Balance sheet as of Aug 31, 2026.

    Full balance sheet

    Cash Flow

    After $9.50M of capital spending, operating cash flow left $369.81M of free cash flow.

    Operating Cash Flow$379.31M
    Capital Expenditures$9.50M
    Free Cash Flow$369.81M
    FCF Per Share$3.56
    Depreciation and Amortization$10.33M

    Trailing 12 months through Aug 31, 2026.

    Full cash flow statement

    Margins

    The operating margin is 41.27%.

    Gross Margin100.00%
    Operating Margin41.27%
    Pretax Margin43.91%
    Net Margin42.01%
    FCF Margin52.68%

    Growth

    Revenue grew 29.55% a year over 3 years.

    Revenue Growth (3Y CAGR)+29.55%
    Revenue Growth (5Y CAGR)+36.35%
    Book Value Per Share Growth (2Y CAGR)+24.29%
    Tangible Book Per Share Growth (2Y CAGR)+24.29%

    Revenue and profit by year

    Dividends and Yields

    NRIX does not pay a dividend. Its free cash flow yield is 23.28%.

    Earnings Yield16.13%
    FCF Yield23.28%
    Buyback Yield-16.08%
    Shareholder Yield-16.08%

    Peer Position

    Against 11 similar companies, NRIX has the lowest P/S.

    P/S Ratio2.3x vs 6.8x median
    Revenue Growth (Trailing 4 Quarters, YoY)+738.76% vs +24.54% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About NRIX

    What is NRIX's market cap?

    Nurix Therapeutics has a market cap of $1.61B. Its enterprise value, which adds debt and subtracts cash, is $889.01M.

    What is NRIX's P/E ratio?

    Nurix Therapeutics has a trailing P/E ratio of 6.2x and a forward P/E of 5.3x.

    How many shares of NRIX are outstanding?

    Nurix Therapeutics has 111.56M shares outstanding. The count is up 32.56% from a year earlier.

    Does NRIX pay a dividend?

    No. Nurix Therapeutics does not pay a dividend.

    How much debt does NRIX have?

    Nurix Therapeutics has $0 of total debt and $720.24M of cash and equivalents, a net cash position of $720.24M.